We have investigated the relationship between the development of tumor resistance towards the cytotoxic action of tumor necrosis factor-a (TNF) and p53 function, using the TNF-sensitive MCF7 human breast adenocarcinoma cell line and two TNF-resistant sublines, MCF7/R-A1 and MCF7/Adr. Use of single-strand conformation polymorphism (SSCP) analysis and DNA sequencing shows that MCF7 has a wild-type p53 gene, whereas both TNF-resistant sublines exhibit mutant p53. This includes a point mutation R280K in MCF7/R-A1 cells, and a point mutation at the splicing acceptor site on the upstream border of exon 5 resulting in a 21 pb deletion in MCF7/Adr cells. These mutations result in loss of p53 capacity to transactivate FASAY (functional assay in yeast). In contrast to what is observed for parental MCF7 cells, treatment of resistant sublines with TNF or g-irradiation fails neither to induce the expression of the p53-regulated gene products p21 waf1/ CIP1 and MDM2, nor to arrest the cells in the G 1 phase of the cell cycle. Disruption of p53 wild-type function in MCF7 cells by transfection with human papillomavirus type-16 E6 gene, leads to abrogation of the cytotoxic, but not the cytostatic activity of TNF. Altogether, our results strongly suggest that wild-type p53 is involved in cytotoxic action of TNF, and point out that loss of p53 function contributes to resistance of tumor cell to TNFinduced killing.
We have investigated the relationship between the development of tumor resistance towards the cytotoxic action of tumor necrosis factor-a (TNF) and p53 function, using the TNF-sensitive MCF7 human breast adenocarcinoma cell line and two TNF-resistant sublines, MCF7/R-A1 and MCF7/Adr. Use of single-strand conformation polymorphism (SSCP) analysis and DNA sequencing shows that MCF7 has a wild-type p53 gene, whereas both TNF-resistant sublines exhibit mutant p53. This includes a point mutation R280K in MCF7/R-A1 cells, and a point mutation at the splicing acceptor site on the upstream border of exon 5 resulting in a 21 pb deletion in MCF7/Adr cells. These mutations result in loss of p53 capacity to transactivate FASAY (functional assay in yeast). In contrast to what is observed for parental MCF7 cells, treatment of resistant sublines with TNF or g-irradiation fails neither to induce the expression of the p53-regulated gene products p21
Introduction
Tumor necrosis factor-a (TNF) is recognized as one of the most pleiotropic cytokines acting as a cytotoxic agent against a variety of tumor cell lines, in addition to its role as a host defence factor in immunological response (Chouaib et al., 1991) . TNF is capable of inducing directly tumor regression with an eciency comparable to that of chemotherapeutic agents and plays a role in tumor regression mediated by cytotoxic T cells. Although locoregional administration of TNF partially resolved its systemic and toxic side eects, resistance of some tumor cells to the cytotoxic action of TNF remains a drawback to its eective application (Lejeune et al., 1994) . Therefore, understanding of the molecular and biochemical mechanisms of tumor cell resistance to the cytocidal action of TNF may ultimately provide new approaches to enhance the therapeutic ecacy of TNF against human malignancies. Although expression of the TNF-receptor alone is necessary for triggering the biological response, it is not sucient to induce the cytolytic process Tsujimoto et al., 1985) . The cytotoxic eect of TNF towards tumor cells can be aected by both intrinsic and acquired cell resistance. Several mechanisms have been reported to contribute to the cellular resistance to TNF-induced cell killing, including the over-expression of several protective proteins in resistant tumor cells, such as manganese superoxide dismutase (MnSOD), endogenous TNF, heat shock protein hsp70, A20 zinc ®nger protein and bcl2 (JaÈ aÈ ttelaÈ et al., 1995 (JaÈ aÈ ttelaÈ et al., , 1992 Opipari et al., 1992; Vanhaesebroeck et al., 1992; Wong et al., 1989) . However, these proteins confer only partial protection against TNF cytotoxicity, suggesting the existence of additional resistance mechanisms.
As many anticancer drugs, TNF induces the generation of reactive oxygen intermediates, DNA damage and apoptotic cell death in tumor cells (Chouaib et al., 1992; Hickman, 1992) . The overexpression of the proto-oncogene bcl2 that can function as an antioxidant, has been shown to partially inhibit the TNF-mediated apoptosis in MCF7 cells (JaÈ aÈ ttelaÈ et al., 1995) . It should be noted that aborted apoptosis in neoplastic cells could be a critical factor in resistance to both natural defences and clinical therapy. It has been reported that one possible mechanism by which proliferating neoplastic cells escape drug targeting is their ability to arrest the cell cycle in response to DNA damage. G 1 /S and G 2 cell cycle checkpoints allow the cell to assess DNA integrity before replication (Hartwell and Kastan, 1994) , while G 1 and G 2 provide the cells time for repair of the antitumor agent-induced damage (Kastan et al., 1991) .
The tumor suppressor protein p53 is constitutively expressed at a very low level in normal cells and mediates cell cycle checkpoints in response to certain types of DNA damage, such as DNA double-strand breaks induced by ionizing radiation (Levine, 1993) . Cell cycle control by p53 occurs through induction of the p21 waf1/CIP1 protein, which is an inhibitor of cyclindependent kinases (El-Deiry et al., 1994) . Once inactivated, cyclin-dependent kinases can no longer phosphorylate target proteins, such as the retinoblastoma RB1 protein (Ewen et al., 1993) , either to release transcription factors such as E2F1 (Nevins, 1992) , which are required for the G 1 to S transition and the initiation of DNA replication. Consequently, cells with increased or stabilised levels of p53 arrest in G 1 (Lin et al., 1992) . The ability of p53 to regulate the cell cycle has been reported to contribute to drug resistance and the apoptosis induced by many anti-cancer agents seems at least in part to be p53 dependent (Lowe, 1995; Lowe et al., 1993) . Interestingly, it has been shown that in some tumor cell lines, TNF induced G 1 arrest followed by DNA degradation and cytolysis (Darzynkiewicz et al., 1984; Pusztai et al., 1993) . Point mutations of the p53 gene are the most frequent genetic alterations in human cancer cells (Iggo et al., 1990; Levine, 1993) . These mutations, resulting in stabilisation and accumulation of high level of a defective p53 product, result in loss of the cell cycleregulating function of the p53 protein and represent a critical step in carcinogenesis. It is therefore conceivable that impairment of wild-type p53 function may also contribute to cell resistance towards the cytotoxic action of TNF. The direct role of p53 in TNF-induced cytotoxicity is still unknown. In order to clarify the involvement of p53 in tumor resistance to TNF, we have studied the p53 status in MCF7 derivative tumor cells (MCF7/R-A1, MCF7/Adr) which have acquired resistance to TNF (Cai et al., 1996 , and determined the consequence of the disruption of p53 wild-type function on the susceptibility of parental MCF7 to TNF.
The results show that resistance of MCF7 derivatives to TNF is associated with loss of p53 function and that wild-type p53 correlates with the susceptibility to the cytolytic eect of TNF.
Results
The development of the resistance of MCF7 cells to TNF is associated with p53 mutation Two TNF-resistant sublines, MCF7/R-A1 and MCF7/ Adr derived from the human breast adenocarcinoma cell line MCF7 were used to establish if alterations of p53 had occurred during development of tumor cell resistance to TNF in vitro. The MCF7/R-A1 cell line was selected by continuous exposure to TNF (Cai et al., 1996) , while MCF7/Adr was found to be TNF resistant subsequent to the development of resistance to adriamycin (Zyad et al., 1994) . The TNF resistance exhibited by MCF7/R-A1 and MCF7/Adr cells was not due to a lack of TNF receptor expression Zyad et al., 1994) . Since MCF7/Adr cells exhibit the classical multidrug resistance (MDR) phenotype associated with overexpression of the Pglycoprotein, a membrane-associated drug eux pump coded by the MDR1 gene (Fairchild et al., 1987) , MDR1-transfected MCF7 cells (MCF7/MDR1) were also included in this study. As shown in Figure 1 , MCF7/R-A1 and MCF7/Adr cells are highly resistant to the cytotoxic eects of TNF compared to parental MCF7 and MCF7/MDR1 cells which are very sensitive to TNF-induced cytotoxicity.
To determine the p53 gene status in TNF-resistant MCF7 cells, SSCP and direct DNA sequencing were performed. PCR-SSCP analysis of genomic DNA reveal the presence of abnormal migrating bands of p53 gene in exon 5 of MCF7/Adr cells (Figure 2a A R280K mutation of p53 gene was detected in MCF7/R-A1 cells, and a point mutation at the last 3' base splicing junction of intron 4 was found in p53 gene of MCF7/Adr cells.
These two points mutations seems to be hemizygous since no corresponding wild-type sequences could be observed.
Sequencing of cDNA synthesised from MCF7/Adr cells showed that the point mutation at the splicing acceptor site on the upstream border of exon 5 resulted in a deletion of the ®rst 21 pb (corresponding to codon 126-133) of the coding region of exon 5 (Figure 3 ).
The p53 mutations in TNF-resistant MCF7/R-A1 and MCF7/Adr cells are associated with loss of p53 transactivation activities
The mutations found in the two TNF-resistant MCF7 sublines are likely to in¯uence the properties of the translated p53 protein. The mutated codon R280 in MCF7/R-A1 is located in the p53 DNA-interaction site (Cho et al., 1994) while the deleted cDNA of MCF7/ Adr should result in a truncated p53 protein (Ogretmen and Safa, 1997) . In order to determine the eect of these mutations on p53 function, a functional assay was carried out in yeast (Flaman et al., 1995) . In this assay, Ade2 7 yeast cells which are grown on medium with limited adenine turn red due to accumulation of an intermediate in adenine metabolism. The yeast strain used for assessment of p53 status (yIG397) contains an integrated plasmid with the Ade2 open reading frame under the control of a p53-dependent responsive promoter. When this strain is transformed with a plasmid containing the wild-type p53 cDNA of parental MCF7, the cells express Ade2, grow normally and form white colonies (Figure 4 ). In contrast, when the yeast cells were transformed with the p53 cDNA isolated from MCF7/R-A1 and MCF7/Adr, red colonies were formed. This suggests that the yeast cells containing the two p53 mutants fail to express Ade2, and consequently could not form white colonies. The cDNA isolated from the red colonies were subjected to sequence analysis and the results con®rmed the mutation and deletion previously observed (data not shown).
Expression of the p53 protein and p53-regulated genes (p21 waf1/CIP1 and MDM2) in TNF-sensitive and -resistant MCF7 cells
The p53-dependent signal transduction pathway induced by ionizing radiation and other DNA damaging agents has been characterized in both normal (Wazer et al., 1994) and cancer cell lines (Kastan et al., 1991; Kuerbitz et al., 1992) . The expression of genes such as p21 waf1/CIP1 and MDM2 can be induced in cells expressing a wild-type p53 protein (Chen et al., 1994; Dulic et al., 1994; El-Deiry et al., 1994) . Our results show that parental MCF7 cells express a barely detectable basal level of p53 protein that was signi®cantly increased after radiation treatment ( Figure 5 ). This accumulation of p53 protein subsequent to irradiation has been attributed to stabilisation of the protein (Kastan et al., 1991) . p21
waf1/CIP1 functions as a universal inhibitor of cyclin-dependent kinase (CDK) activities in cells that have sustained DNA damage (Dulic et al., 1994; ElDeiry et al., 1994) , while MDM2 is a p53-inducible gene that functions in a feedback loop to inhibit the transcriptional activity of p53 (Barak et al., 1993; Momand et al., 1992; Wu et al., 1993) . The basal levels of p21 waf1/CIP1 and MDM2 protein were low in parental MCF7 cells and increased signi®cantly after treatment with ionizing radiation. In contrast, the TNFresistant cell lines, MCF7/R-A1 and MCF7/Adr, expressed high levels of mutant p53 protein constitutively which did not increase further after treatment with ionizing radiation ( Figure 5 ). No expression of the p53-regulated proteins p21 waf1/CIP1 and MDM2 was observed in the two TNF-resistant cell lines even after irradiation.
Absence of G 1 arrest in TNF-resistant MCF7/R-A1 and MCF7/Adr cells after irradiation or treatment with TNF It is well established that treatment with DNA damaging agents results in cell cycle arrest in G 1 in cells expressing functional p53 protein (Di-Leonardo et al., 1994; El-Deiry et al., 1994; Kastan et al., 1991; O'Connor et al., 1993) .
It has also been shown that the two main components of the growth inhibition activity of TNF on tumor cells in vitro consist of an early cytostatic , and subjected to PCR-SSCP analysis of exon 5 and exon 8 of p53 gene. Electrophoresis was carried out in a 5% Hydrolink MDE gel containing 8% glycerol and run at room temperature. (b) Sequence analysis of PCR products ampli®ed from the genomic DNA of p53 gene fragments covering exon 5 (for MCF7/Adr) and exon 8 (for MCF7/R-A1). Sense sequences are shown for both exon 5 and exon 8. Arrows indicate the two dierent p53 gene points mutations in MCF7/R-A1 and MCF7/Adr. SSCP experiments as well as sequencing were repeated twice to exclude any PCR-induced mutations p53 and TNF-induced cell death Z Cai et al eect (G 1 block), followed by nuclear shrinkage and cytolysis (Pagliacci et al., 1993) .
The cell cycle distribution of exponentially growing TNF-sensitive or -resistant MCF7 cells subsequent to treatment with TNF or g-irradiation was carried out in order to establish the eect of the p53 mutations on the G 1 block.
Our data indicate that untreated control cells contained two discrete populations, G 1 and G 2 /M, with an intermediate S phase DNA population ( Figure  6 , lanes a1, b1 and c1). When parental MCF7 cells were treated with 50 ng/ml TNF for 24 h, a signi®cant accumulation of the G 0 /G 1 population and a reduction of the S phase cells followed by a disappearance of the G 2 /M compartment were observed (Figure 6 lane a2) . After 40 h treatment with TNF, 30% of the cells initially blocked in the G 1 phase were found to contain a sub-G 1 DNA content typical of apoptotic cells ( Figure 6 , lane a3). The microtubule inhibitor nocodazole was added after 24 h treatment with TNF for 16 h further incubation. This inhibitor is able to arrest cells in metaphase which allows the identi®cation of the true G 1 -arrested cell population (O'Connor et al., 1993) .
The results depicted in Figure 6 (lane a4) demonstrated the existence of an eective G 1 arrest after 24 h treatment with TNF, since the addition of nocodazole for further 16 h incubation resulted only in a modest increase of cells in the G 2 /M phase, compared to the predominant arrest in the G 2 /M phase after 16 h incubation with nocodazole alone (lane a7). Sixteen hours after treatment with ionizing radiation (5 Gy), parental MCF7 cells showed a prominent G 1 peak with a large decrease of cells in S and MDM2 Figure 5 Western-blot analysis of p53, p21 waf1/CIP1 and MDM2 proteins. Total protein (100 mg/lane) extracted from untreated control cells (C) or g-irradiated cells 5 h after exposure to 5 Gy (X) was separated on 7.5% SDS-polyacrylamide gels, transferred to nitrocellulose membranes and probed for expression of p53, p21 waf1/CIP1 and MDM2 proteins by use of speci®c antibodies p53 and TNF-induced cell death Z Cai et al radiation resulted in a prominent G 1 peak and an increased G 2 /M peak (lane a6). This pro®le is indicative of cells that arrest in G 1 after treatment with ionizing radiation and correlates with the wild-type p53 status of parental MCF7 cells. In contrast, the TNF-resistant counterparts MCF7/ R-A1 and MCF7/Adr showed no detectable G 1 arrest after either treatment with TNF for 24 h (Figure 6,   lanes b2, c2) and 48 h (lanes b3, c3) or treatment with ionizing radiation (lanes b5, c5) .
The addition of nocodazole after 24 h treatment with TNF or g-irradiation for a further 16 h incubation period showed a predominant arrest of MCF7/R-A1 and MCF7/Adr in the G 2 /M phase of the cell cycle (lanes b4 and c4, b6 and c6), which was comparable to the treatment of nocodazole alone (b7, c7). Cs source delivering g-ray at a dose rate of 1.6 Gy/min. Cells were collected for propidium iodide staining and¯ow cytometric analysis was performed as described in Materials and methods. One representative experiment of three independent experiments is shown This con®rms the failure of TNF and ionizing radiation to induce G 1 arrest and apoptosis in the two TNF-resistant counterparts of MCF7 cell line.
Disruption of p53 wild-type function by E6 gene transfection protects MCF7 cells from TNF-induced apoptosis
The previous results show that the development TNF resistance in MCF7/R-A1 and MCF7/Adr cells was accompanied p53 mutations and the abrogation of G 1 arrest subsequent to ionizing radiation. TNF also failed to induce G 1 arrest and the subsequent apoptotic cell killing in these cells. Since the parental MCF7 cells expressed a wild-type p53 protein, we were in a unique position to determine the eect of p53 on the susceptibility of these cells to the cytotoxic action of TNF by disrupting the p53 wild-type function. The human papillomavirus type-16 E6 gene product has been reported to stimulate the degradation of p53 through the ubiquitin pathway (Crook et al., 1991; Schener et al., 1990) . MCF7/E6 cells exhibited high expression level of the E6 gene product which decreased the level of p53 protein and impaired the response to g-irradiation-induced accumulation of p53 and p21 waf1/CIP1 proteins (Fan et al., 1995) . Impairment of G 1 arrest induced by ionizing radiation in these E6-transfected MCF7 cells is clearly illustrated in The cytotoxic eect of TNF on these cells was examined by kinetic analysis. Similar to parental MCF7 (Figure 6 ), a G 1 arrest was detected in control MCF7/CMV cells 24 h after treatment with TNF ( Figure 7, lane A1) .
In response to TNF, the cells were ®rst blocked in the G 1 phase and then underwent apoptotic cell death. Following 40 ± 72 h treatment with TNF ( Figure 7 , lanes A3 ± 5), more and more cells were found to contain a sub-G 1 DNA content and the number of cells in G 1 decreased.
The addition of nocodazole after 24 h treatment with TNF ( Figure 7 , lane A6) did not induce an accumulation of G 2 /M cells and could not prevent the cells from undergoing apoptosis, con®rming that the G 1 arrest and subsequent apoptosis were induced by TNF in these cells. G 1 arrest was also observed in MCF7/E6 cells following treatment with TNF and persisted from 24 ± 72 h treatment (Figure 7 , B2-5), but with no cells in the apoptotic phase until after 72 h when the maximum cell killing was detected in parental MCF7 and MCF7/CMV cells. Addition of nocodazole did not induce an accumulation of cells in G 2 /M phase ( Figure 7, lane B6) . The proliferation assay further con®rmed the G 1 arrest and the cytostatic eect of TNF on MCF7/E6 cells (data not shown). Thus, in MCF7 cells, disruption of p53 wild-type function resulted in a loss of the cytotoxic eect of TNF without overcoming the cytostatic eect of TNF.
Discussion
Tumor cell apoptosis can be induced by several stimuli, including anti-cancer drugs and triggering of a number of structurally related cell-surface receptors such as TNF receptors (Chouaib et al., 1991; Hickman, 1992) . TNF has been shown to play a role in the killing of tumor cells by activated macrophages and cytotoxic lymphocytes known to contribute to the early stages of antitumor surveillance. This cytokine was also found to be capable of inducing tumor regression comparable to that of chemotherapeutic agents. Therefore resistance of tumor cells to the cytotoxic action of TNF may be crucial to the development of primary tumors in vivo. Despite substantial progress made in the understanding of the mechanisms of TNF-induced tumor cell death, the major aspects of the resistance to the cytotoxic action of this cytokine remain poorly understood. Therefore better understanding of the genetic mechanisms which modulate TNF-induced apoptosis may be of particular importance in the control of tumor progression. Apoptotic cell death is an active process which depends on the expression of speci®c genes. A large body of evidence suggests that some oncogenes are involved in the regulation of tumor susceptibility to the apoptotic action of TNF, including c-myc, bcl2 and bax (JaÈ aÈ ttelaÈ et al., 1994 Klefstrom et al., 1994) . The present study provides evidence that an alteration of p53 function is associated with an abrogation of TNF-induced cytotoxicity and the subsequent acquisition of tumor cell resistance to this cytokine. The demonstration of the loss of function of p53 mutation in TNF-resistant human breast cancer cells strongly suggest that the impairment of wild-type p53 function may contribute to tumor cell resistance towards both the cell cycle arrest and the apoptotic eect of TNF. In agreement with these observations, the absence of wildtype p53 function has recently been reported to play a direct role in mediating the resistance of human colon cancer to a wide variety of chemotherapeutic drugs . Yin et al. have reported that TNF was able to induce an increase in wild-type p53 expression and a decrease of mutated p53 expression in rat glioma cells (Yin et al., 1995) , suggesting the existence of a relationship between p53 and the apoptosis-induced by TNF. Under our experimental condition, TNF does not appear to have an eect on p53 induction in MCF7 cells (data not shown).
The expression of p53 seems not to be a direct target of TNF signaling in this cell model and the susceptibility of tumor cells to TNF is dependent of the wild-type p53 function. However it should be noted that in some p53 de®cient myeloid leukemic cell lines (K562, HL60), TNF was ecient to induce a cytostatic eect (Shiohara et al., 1996) . This further con®rms that TNF has strikingly dierent eects according to the cell type.
The control of TNF-induced cell killing by p53 may occur at several levels. Evidence has been provided indicating that the generation of reactive oxygen radicals, resulting in mitochondrial damage and DNA degradation, is a potential mechanism for TNFmediated cell lysis. Furthermore, the accumulation of reactive oxygen species and the subsequent induced-cell death was suggested to involve a process that might be controlled by levels of proto-oncogene bcl-2 (Owen- Schaub et al., 1992) . It has become clear that p53 acts as a transcriptional regulator of bcl-2 and bax gene expression in vitro and in vivo (Miyashita et al., 1994) . Obviously, p53 may down-regulate the expression of bcl-2 through the presence of a p53-dependent negative response element in the bcl-2 gene (Miyashita and Reed, 1995) . While bcl-2 has been shown to inhibit p53-dependent apoptosis (Chou et al., 1994) and to confer partial protection against the apoptotic eect of TNF (JaÈ aÈ ttelaÈ et al., 1995), we and others have provided evidence for the lack of correlation between cellular bcl-2 gene expression and the resistance of MCF7 derivative cells to TNF-induced cytotoxicity (Caignard et al., 1997; Vanhaesebroeck et al., 1993) . Based on these observations, it is ruled out that p53 mutation in TNF resistant cells confers resistance to the cytotoxic action of TNF through modulation of bcl-2 gene expression.
Furthermore, the presence of a p53 responsive element in the human bax promoter provides a basis for the p53-dependent activation of bax expression (Miyashita and Reed, 1995) . It should be noted that cells from bax-de®cient mice show a normal p53 dependent apoptotic response following exposure to ionizing radiation (Knudson et al., 1995) suggesting that the activation of Bax by p53 is not an obligate step in the instigation of apoptosis. This is in agreement with our recent ®nding ruling out the implication of bax in the MCF7 resistance to TNF-induced cell killing (Caignard et al., 1997) .
The role of p53 in the control of apoptosis triggered by TNF is further con®rmed by experiments demonstrating that the disruption of wild-type p53 protein in MCF7/E6 cells resulted in loss of the apoptotic activity of TNF. This provides a direct evidence for the association between loss of p53 function and the resistance of MCF7 cells to TNF-induced cell killing. The fact that MCF7/E6 cells retain TNF-induced G 1 arrest ability may be explained by the nature of the p53 disruption in these cells. In fact, the E6-transfectioninduced p53 alteration, does not appear to have the same consequence than mutation-related p53 wild-type function loss in TNF-resistant MCF7/R-A1 and MCF7/Adr cells. While in these two cell lines, G 1 phase signi®cantly decreased following g-irradiation and whereas these cells were resistant to both cytostatic and cytotoxic eect of TNF, in MCF7/E6 a normal G 1 phase and a slightly increased G 2 phase following girradiation were observed (Figure 7 ). These dierences could be explained by the fact that the degradation of endogenous p53 by the expression of the E6 transgene through the ubiquitin pathway does not have the same eect than a gain of the mutant p53 function which may dominantly act by blocking wild-type p53 function. However, MCF7-E6 cells do not appear to be susceptible to the cytotoxic action of TNF since when TNF is removed 24 h after treatment, these cells can regain their growth (data not shown) suggesting that the p53 disruption resulted only in the induction of a reversible cytostatic eect.
It is well known that p53 and the oncoprotein c-myc cooperate in apoptosis induction (Hermeking and Eick, 1994) . Wild-type p53 expression has been shown to be required for apoptosis induction in human and murine ®broblast cells overexpressing c-myc (Wagner et al., 1994) .
Furthermore, induction of c-myc has also been reported to be involved in the triggering of TNFmediated apoptosis (JaÈ nicke et al., 1994; Klefstrom et al., 1994) . It has become clear that TNF induced a cell growth arrest signal (Pagliacci et al., 1993) which is one way to trigger apoptosis induced by overexpression of c-myc (Evan et al., 1992; Fernandez et al., 1994) .
p53 and TNF-induced cell death Z Cai et al Indeed, our data indicate clearly that TNF induced G 1 arrest and subsequent apoptosis in sensitive MCF7 displaying wild-type p53. This is consistent with our previous ®nding showing that TNF was capable of inducing c-myc expression in sensitive parental MCF7 cells (Caignard et al., 1997) . On the contrary, TNF failed to induce neither G 1 arrest and apoptosis, nor c-myc expression in TNF-resistant MCF7/R-A1 and MCF7/Adr cells expressing mutant p53. It is conceivable that the degradation of endogenous wild-type p53 in MCF7-E6 cells may result from a possible absence of p53 and c-myc cooperation, and consequently, these cells arrested on G 1 phase but did not undergo apoptosis after treatment with TNF. However, it remains to be determined whether mutant p53 is involved in the cytostatic eect of TNF and whether c-myc induction contributes to G 1 arrest induced by TNF.
It is pertinent to note that acquired resistance of tumor cells to apoptosis is a major concern in cancer therapy, particularly in cases of recurrent disease (Harrison, 1995) . In several haematological malignancies, p53 mutations are directly associated with chemoresistance and shortened survival, and in certain solid tumors, p53 mutations are associated with reduced apoptosis in tumors that are refractory to therapeutic intervention (Lowe, 1995) . Our studies demonstrate that p53 mutation was associated with the acquisition of tumor resistance to the cytotoxic action of TNF. Adenovirus-based transfer of wild type p53 gene has been recently reported to increase ovarian tumor radiosensitivity (Gallardo et al., 1996) . In our experimental system, such a transfer resulted in restoration of the susceptibility to TNF-induced cell killing in TNF resistant cells (data not shown). It would be of major interest to evaluate critically in vivo the role of p53 wild-type function as a determinant of tumor susceptibility to the cytotoxic action of TNF.
The clinical use of TNF associated with transfer of the wild-type p53 gene could be a new alternative to overcome tumor resistance to this cytokine and may be important for developing more eective therapeutic intervention. The identi®cation of the molecular targets of p53 within tumor cells and understanding how this tumor suppressor gene facilitates TNF-induced apoptosis may be of major interest in the elucidation of TNF-mediated cell killing.
Materials and methods

Cell lines and cultures
MCF7 is a well characterized human cell line derived from a metastatic breast adenocarcinoma. TNF-resistant MCF7/ R-A1 cells were derived from the TNF-sensitive MCF7 after continuous exposure to increasing doses of recombinant TNF-a (Cai et al., 1996) . MCF7/Adr cells were obtained by continuous exposure of MCF7 cells to increasing concentrations of adriamycin (Fairchild et al., 1987) . MCF7/MDR1 cells (Clone 10.3, kindly provided by Dr R Clarke, Lombardi Cancer Research Centre, Washington) show a stable MDR phenotype in vitro and were obtained by infection of MCF7 cells with pHaMDR1/A retrovirus leading to constitutive expression of the MDR1 gene product. MCF7-CMV and MCF7-E6 cells (kindly provided by Dr PM O'Connor, NIH) were obtained by transfection of MCF7 cells with the pCMV vector or the human papillomavirus type-16 E6 gene cloned into pCMV (Fan et al., 1995) . All cell lines were routinely cultured in RPMI 1640 medium containing 5% FCS, 1% penicillinstreptomycin, 1% L-glutamine at 378C in a humidi®ed atmosphere with 5% CO 2 .
Determination of cellular sensitivity to TNF
Cell viability was determined using crystal-violet staining as previously described (Zyad et al., 1994) . Cells were seeded in¯at-bottomed 96-well plates (7500 cells/well), and human recombinant TNF-a was added. Highly puri®ed (499%) recombinant TNF (speci®c activity 6.63610 6 U/mg protein) was kindly provided by AG Knoll (BASF, Ludwigshafen, Germany). After incubation at 378C for 72 h, the medium was replaced with 100 ml of a 0.5% crystal-violet solution. After 10 min incubation at room temperature, the plates were washed and viable crystalviolet-stained cells were lysed with a 1% SDS solution. The absorbance (A), which is proportional to cell viability, was measured at 540 nm. TNF mediated cell lysis could be determined by comparing the viability of untreated cells with that of treated cells using the following equation: Cell viability (%)=1006(A 1 /A 0 ), cell lysis (%)=100%7cell viability (%), where A 1 and A 0 were the absorbance obtained from treated and untreated cells, respectively. The mean value of quadruplicate from each experiment was used for anlaysis.
PCR ± SSCP analysis and direct DNA sequencing SSCP (single-strand conformation polymorphism) analysis was performed on the entire coding region of the p53 gene as described previously by Lazar et al. (1994) . Amplification was performed with 320 ng extracted cellular genomic DNA, 3 pmol of each primer, 5 mM dNTPs, 2 mCi of [a-
33 P]dATP, 1.25 mM MgCl 2 , 16PCR II buer (Pharmacia) and 0.5 units of Taq polymerase (Perkin Elmer) in a ®nal volume of 20 ml. The primers which were previously described (Lazar et al., 1994) allow the study of the entire coding region of p53 (exon 2 ± 11 of the p53 gene), including¯anking intron sequences. DNA ampli®cation was carried out in a Thermal Cycler (Perkin Elmer 9600) by 30 cycles of PCR (30 s at 958C, 30 s at 588C and 30 s at 728C). PCR products were then denatured and migrated in a non-denaturing Hydrolink MDE gels (Bioprobe) with 8% glycerol at room temperature or without glycerol at 48C for 18 h at 8 W. Gels were dried at 808C under vacuum and exposed to X-ray ®lms at room temperature.
Sequencing of the PCR products from extracted genomic DNA was performed after ampli®cation (through 30 cycles of 1 min at 958C, 1 min 30 s at 588C and 1 min 30 s at 728C) using the initial symmetric ampli®cation primers for exons 5 and 8 (Baker et al., 1990) . Similar experimental conditions were used to carry out second asymmetric ampli®cations, with only one primer for each exon. Finally, the asymmetric PCR products were puri®ed and sequenced with a T7 sequencing kit (Pharmacia). Sequencing of the RT-PCR products from total RNA was performed using the primers for exon 5 and exon 8 coding cDNA regions.
p53 functional assay in yeast
Total RNA was extracted from the dierent tumor cell lines according to the method of Chomczynski and Sacchi (1987) and reverse-transcribed using super-script reversetranscriptase and oligo(dT) primers according to the manufacturer's instructions (Gibco-BRL, Bethesda, MD). p53 functional assay using yeast transformation method was performed as previously described (Flaman et al., 1995) . 
Western blot analyses
Cells (1610 7 ) were suspended in ice-cold lysis buer (50 mM Tris-HCl pH 6.8, 2% SDS, 100 mM DTT, 1 mM aprotinin), sonicated for 15 s and then incubated for 10 min at 48C. Equivalent protein extracts were separated by SDS ± PAGE and transferred to Immobilon-P polyvinyldivinyl¯uoride transfer membrane (Millipore Corp.). After blocking with 5% non-fat dry milk and 2% glycine in PBS buer, blots were probed with the appropriated monoclonal antibody overnight at 48C. Mouse monoclonal antibodies to p53 (DO1, Santa Cruz, USA), p21 waf1/CIP1 (Ab-1, Oncogene Science, USA) and MDM2 (IF2, Oncogene Science, USA) were used. After washing and further incubation with a goat anti-mouse IgG (ICN, UK) , the blots were revealed with [
125 I]protein A (Amersham, les Ulis, France) followed by exposure to X-ray ®lm.
Cell cycle analysis
Samples were prepared for¯ow cytometry as described previously (O'Connor et al., 1993) . Brie¯y, cells were ®xed in ice-cold 70% ethanol, washed with PBS and stained with propidium iodide (10 mg/ml, Sigma) at 378C for 30 min in the presence of RNase (100 mg/ml, Sigma). Cell cycle analysis was performed using an EPICS pro®le II (Coulter electronic, Margency, France). A minimum of 10 000 cells were analysed for each point, and quantitation of cell cycle distribution was performed using the Multicycle AV model program provided by the manufacturer.
